News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
561,712 Results
Type
Article (38702)
Company Profile (93)
Press Release (522917)
Section
Business (174341)
Career Advice (2159)
Deals (28681)
Drug Delivery (79)
Drug Development (61720)
Employer Resources (145)
FDA (13845)
Job Trends (12578)
News (285041)
Policy (27005)
Tag
Academia (2180)
Alliances (44682)
Alzheimer's disease (1032)
Approvals (13801)
Artificial intelligence (114)
Bankruptcy (260)
Best Places to Work (9812)
Breast cancer (102)
Cancer (844)
Career advice (1820)
Cell therapy (189)
Clinical research (48258)
Collaboration (314)
Compensation (94)
COVID-19 (2591)
C-suite (73)
Data (816)
Diabetes (123)
Diagnostics (6279)
Drug pricing (70)
Earnings (71569)
Employer resources (131)
Events (83549)
Executive appointments (218)
FDA (14226)
Funding (248)
Gene therapy (129)
GLP-1 (492)
Government (3873)
Healthcare (15421)
Infectious disease (2676)
Inflammatory bowel disease (87)
Interviews (391)
IPO (12854)
Job creations (3076)
Job search strategy (1540)
Layoffs (359)
Legal (6669)
Lung cancer (132)
Manufacturing (142)
Medical device (10522)
Medtech (10526)
Mergers & acquisitions (15870)
Metabolic disorders (318)
Neuroscience (1245)
NextGen Class of 2024 (5253)
Non-profit (3779)
Northern California (1038)
Obesity (179)
Opinion (205)
Patents (85)
People (46817)
Phase I (14804)
Phase II (20792)
Phase III (16773)
Pipeline (306)
Postmarket research (2172)
Preclinical (6318)
Press Release (70)
Radiopharmaceuticals (221)
Rare diseases (151)
Real estate (4841)
Regulatory (17538)
Research institute (1998)
Resumes & cover letters (335)
Southern California (893)
Startups (2864)
United States (9835)
Vaccines (645)
Weight loss (139)
Date
Today (100)
Last 7 days (784)
Last 30 days (2708)
Last 365 days (28787)
2024 (25527)
2023 (32565)
2022 (42847)
2021 (46333)
2020 (45278)
2019 (38440)
2018 (28968)
2017 (27348)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (832)
Arizona (130)
Asia (32158)
Australia (5573)
California (2237)
Canada (982)
China (171)
Colorado (107)
Connecticut (125)
Europe (76205)
Florida (335)
Georgia (89)
Illinois (261)
Indiana (149)
Kansas (75)
Maryland (463)
Massachusetts (1810)
Michigan (150)
Minnesota (198)
New Jersey (753)
New York (740)
North Carolina (597)
Northern California (1038)
Ohio (104)
Pennsylvania (587)
South America (1053)
Southern California (893)
Texas (324)
Utah (74)
Washington State (254)
561,712 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.
October 10, 2024
·
2 min read
·
Tristan Manalac
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Vaccines
5 Late-Stage mRNA Vaccines to Watch
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the market for cancer, influenza and more.
September 16, 2024
·
5 min read
·
Ben Hargreaves
Business
Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance
Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.
January 17, 2024
·
2 min read
Pharm Country
Quest Diagnostics Releases 2023 Corporate Responsibility Report
Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.
June 27, 2024
·
3 min read
NextGen
10 Years of NextGen Honorees: Where Are They Now?
BioSpace
has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at noteworthy companies from each of those lists.
October 30, 2024
·
8 min read
·
Annalee Armstrong
Drug Development
First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo
September 5, 2024
·
4 min read
Press Releases
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
September 2, 2024
·
9 min read
Approvals
Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population
The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.
September 18, 2024
·
2 min read
·
Tristan Manalac
BioCapital
Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
April 11, 2024
·
2 min read
1 of 56,172
Next
